Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

During Pancreatic Cancer Awareness Month, CancerNetwork® spoke with Kelly A. Rone, DNP, RN, AGNP-c, about the current state of pancreatic cancer, emphasizing risk factors, diagnostic challenges, and treatment planning. Rone is an advanced practice nurse of gastrointestinal oncology at Mayo Clinic in Phoenix, Arizona.

Rone initially discussed patient counseling for risk factors, making a distinction between modifiable risk factors—such as smoking, drinking, and obesity—and nonmodifiable risk factors, which primarily include genetic syndromes. Rone then highlighted a need for more effective screening methods, highlighting a lack of screening tools that have been proven to be highly effective, as well as the tendency for pancreatic cancer to be identified at a later stage.

Rone then touched upon treatment-emergent adverse effects (AEs), as well as how her practice manages them. She particularly placed emphasis on appetite loss, which may prove difficult for patients attempting to recover from cancer treatment. Additionally, Rone suggested various methods to encourage food consumption in spite of appetite loss.

Rone expressed that she connects patients with pancreatic cancer to palliative care frequently, explaining that patients can benefit from involvement in terms of managing AEs and extending life expectancy. Furthermore, she stressed a need to correct misconceptions of palliative care as exclusively entailing pre-hospice care, highlighting benefit in all patients regardless of disease stage.

Rone iterated that addressing psychosocial needs for patients varies depending on a patient’s circumstances. Rone then suggested that viewing patients as individuals with lives beyond their cancer diagnosis can help humanize them and can help to foster more meaningful discussions regarding cancer treatment than electronic health records alone.

Then, Rone expressed a desire to find ways to detect pancreatic cancers sooner by developing biomarkers, highlighting how pancreatic cancer may be paired with several vague symptoms that make early detection difficult. Rone explained that early detection of pancreatic cancers can be associated with better outcomes.

She further expressed a need to elicit better treatment outcomes for pancreatic cancer based on low responsiveness to chemotherapy. Rone concluded by emphasizing a need for education regarding 2 distinct types of pancreatic cancer––pancreatic adenocarcinoma and pancreatic neuroendocrine cancer––to better manage patient expectations.